Iliac Artery Balloon Catheter Little Benefit in Placenta Accreta

This article originally appeared here.
Share this content:
Iliac Artery Balloon Catheter Little Benefit in Placenta Accreta
Iliac Artery Balloon Catheter Little Benefit in Placenta Accreta

WEDNESDAY, April 19, 2017 (HealthDay News) -- Prophylactic placement of internal iliac artery balloon catheters does not impact outcomes for women with placenta accreta, according to a study published online April 12 in Anaesthesia.

Shimiao Feng, from the Sichuan University in Chengdu, China, and colleagues conducted an impact study on the introduction of routine placement of internal iliac artery balloon catheters for management of hemorrhage during cesarean section. Data were included for 11 women with prenatally diagnosed placenta accreta/increta/percreta who acted as controls and 30 women who had iliac artery balloon placement; in 27 cases the balloons were inflated.

The researchers found that the median intraoperative blood loss was 1,100 and 1,000 mL in controls and women with iliac artery balloons, respectively (P = 0.64). Intraoperative blood transfusion was received by 54 percent of controls and 47 percent of women with iliac artery balloons (P = 0.66). Cesarean hysterectomy was performed in 27.3 and 43.3 percent of controls and women with iliac artery balloons, respectively (P = 0.48). There was a correlation for balloon catheter insertion with shortened postoperative hospital stay (six versus five days; P = 0.033). General anesthesia was used in 54 percent of controls and 100 percent of women with iliac artery balloons.

"This study demonstrates that prophylactic balloon occlusion of the internal iliac arteries did not reduce intra-operative hemorrhage or caesarean hysterectomy in women with placenta accreta undergoing caesarean section," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »